Aprea Therapeutics to Showcase Innovations at Investment Conference
Aprea Therapeutics, an innovative biopharmaceutical company, is making significant progress in the field of precision oncology. Based in Doylestown, Pennsylvania, Aprea is recognized for its dedication to synthetic lethality—a revolutionary approach that targets cancer cells by taking advantage of their unique weaknesses.
Presentation Details at H.C. Wainwright Conference
At the upcoming H.C. Wainwright 26th Annual Global Investment Conference, Dr. Oren Gilad, President and CEO of Aprea Therapeutics, will deliver an insightful presentation. Scheduled for September 10, this event is anticipated to be a key moment for investors and stakeholders eager to learn about the latest advancements in cancer therapies.
What to Expect from the Presentation
In his presentation, Dr. Gilad will outline Aprea's forward-thinking approach to cancer treatment, highlighting their lead program, ATRN-119. This clinical-stage small molecule ATR inhibitor is being developed for a range of solid tumor indications. Additionally, Aprea is progressing with its second promising candidate, APR-1051, an oral WEE1 inhibitor that has recently entered clinical trials.
Event Logistics
The conference will take place at the Holmes II within the Lotte New York Palace Hotel. Attendees can look forward to a detailed overview of Aprea's innovative cancer-fighting strategies during Dr. Gilad's session, which will begin at 9 AM Eastern Time. For those unable to attend in person, a live webcast of the presentation will be available, and it will also be archived on Aprea's corporate website for later viewing.
Enhancing Investor Relations
Aprea Therapeutics recognizes the importance of clear communication with its investors. Their dedicated management team will be available for one-on-one meetings with institutional investors during the conference. Interested individuals are encouraged to contact their conference representatives to arrange a meeting.
About Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapies aimed at treating various cancers through the concept of synthetic lethality. Their extensive pipeline of candidates continues to grow, driven by a scientific approach that emphasizes precision and effectiveness in oncology.
Continued Commitment to Disclosure
Aprea is dedicated to using its investor relations website as a platform for sharing significant nonpublic information, ensuring compliance with disclosure obligations under Regulation FD. This proactive strategy highlights their commitment to transparency in all communications.
Investor Contact Information
For any inquiries related to investments or meetings, Mike Moyer from LifeSci Advisors is the designated contact person. Investors can reach out to him via email.
Frequently Asked Questions
1. What is Aprea Therapeutics known for?
Aprea Therapeutics is recognized for its focus on precision oncology and the development of innovative therapies that utilize synthetic lethality to combat cancer.
2. Who will present at the H.C. Wainwright Conference?
Dr. Oren Gilad, the President and CEO of Aprea Therapeutics, will be the presenter at the conference.
3. When is the H.C. Wainwright Conference taking place?
The conference is set for September 9-11, with Aprea's presentation scheduled for September 10.
4. How can I access the presentation online?
The presentation will be available through a live webcast and will also be archived on Aprea’s corporate website for future viewing.
5. Who can I contact for investor relations?
For inquiries related to investor relations, Mike Moyer from LifeSci Advisors is the appropriate contact person.
